Fusion Antibodies plc (AIM:FAB)

Fusion Antibodies Cash Flow Statement

Financials in millions GBP. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-1.71	-2.23	-2.6	-1.2	-2.9
Depreciation & Amortization	0.11	0.22	0.37	0.75	0.71
Other Amortization	-	-	-	0	0
Stock-Based Compensation	0.04	0.09	0.04	0.02	0.02
Other Operating Activities	0.04	0.22	-0.13	-0.02	1.72
Change in Accounts Receivable	-0.08	0.13	0.82	-0.08	-0.55
Change in Inventory	0.19	0.08	0.05	-0.11	-0.14
Change in Accounts Payable	0.05	-0.28	-0.3	0.31	0.01
Operating Cash Flow	-1.36	-1.77	-1.75	-0.33	-1.14
Capital Expenditures	-0.01	-0	-0.11	-0.26	-0.37
Other Investing Activities	0.01	0	0	0	0
Investing Cash Flow	-0.01	0	-0.11	-0.26	-0.36
Long-Term Debt Issued	-	-	0.07	-	0.01
Long-Term Debt Repaid	-0.02	-0.03	-0.06	-0.16	-0.16
Net Debt Issued (Repaid)	-0.02	-0.03	0.01	-0.16	-0.15
Issuance of Common Stock	0.56	2.81	-	0.12	3.02
Other Financing Activities	-0	-0.01	-0	-0.01	-0.22
Financing Cash Flow	0.53	2.77	0	-0.06	2.65
Foreign Exchange Rate Adjustments	-	0	0.01	0.01	-
Net Cash Flow	-0.84	1	-1.85	-0.64	1.15
Free Cash Flow	-1.37	-1.77	-1.87	-0.59	-1.5
Free Cash Flow Margin	-69.92%	-155.90%	-64.39%	-12.25%	-36.04%
Free Cash Flow Per Share	-0.01	-0.03	-0.07	-0.02	-0.06
Cash Interest Paid	0	0.01	0	0.01	0.02
Cash Income Tax Paid	-0.11	-0.28	-0.13	-0.1	-0.07
Levered Free Cash Flow	-0.75	-0.97	-1.08	-0.22	-1.17
Unlevered Free Cash Flow	-0.75	-0.97	-1.07	-0.22	-1.16
Change in Working Capital	0.17	-0.07	0.57	0.12	-0.69

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.